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SUMMARY
Psoriasis is a chronic relapsing, remitting interleukin
(IL)-23/IL-17-driven skin disease mediated by the
interplay of T cells and polymorphonuclear granulo-
cytes. Although preclinical studies have provided in-
sights into the mechanisms of disease initiation, the
underpinnings of natural disease remission remain
largely unknown. Here, we addressed the contribu-
tion of regulatory Foxp3+ T cells (Treg cells) in psor-
iasiform skin inflammation and remission using the
Aldara-skin inflammation model in combination with
the inducible depletion of Foxp3+ Treg cells. Loss
of Treg cells exacerbated skin inflammation, but
this did not involve increased gd T cell expansion or
the local production of the psoriasis-associated cy-
tokines IL-17A, IL-17F, and IL-22, which are the
main driving forces of disease development. Instead,
Treg cells suppressed the infiltration of granulocyte-
macrophage colony-stimulating factor (GM-CSF)-
producing CD4+ T cells into the lesioned skin, and
neutralizing GM-CSF in Treg cell-deficient mice
reversed hyper-inflammation, resulting in disease
regression. Therefore, we identified a non-redundant
role of Treg cells restraining skin inflammation and
mediating skin homeostasis.
INTRODUCTION
Psoriasis is one of the most common immune-mediated inflam-
matory disorders affecting 2%–3% of the world’s population
(Perera et al., 2012). To date, several forms of psoriasis have
been described, including guttate, inverse, erythrodermic,
arthritic, and plaque psoriasis (Menter et al., 2008). Plaque psori-
asis, characterized by inflamed silver-white scaly skin, hyper-pro-
liferation of keratinocytes, and dermal infiltrates of immune cells,
is the most common form of psoriasis found in 85%–90% of
patients (Nestle et al., 2009). Psoriasis patients suffer from a
high disease burden and associated comorbidities, such as
Crohn’s disease (Gelfand et al., 2004; Nestle et al., 2009), type II
diabetes (Yu et al., 2009; Shapiro et al., 2007), cardiovascular
diseases (Perera et al., 2012; Davidovici et al., 2010), lymphoma
(Gelfand et al., 2006), and depression (Kurd et al., 2010). Until
today, the trigger causing this relapsing-remitting skin disease re-
mains unknown. However, genetic predisposition in psoriasis-
susceptible loci (PSORS) has been linked to psoriasis, including
SNPs of the HLA.Cw6, interleukin-12b (IL-12b), or IL-23R loci
(Nair et al., 2009). More recently, studies in human and mice
unambiguously identified IL-23 and IL-17 as pathogenic drivers
of this disease (Becher and Pantelyushin, 2012; Pantelyushin
et al., 2012; Di Cesare et al., 2009). IL-17 is mainly produced by
activated Th17 cells, gdT cells, and type 3 innate lymphoid cells
(ILCs) in response to dendritic cell (DC)-derived IL-1b and IL-23
(Becher and Pantelyushin, 2012; Baliwag et al., 2015).
One hallmark of psoriasis is the relapsing-remitting nature
(Perera et al., 2012). Whereas dysregulated production of IL-
23/IL-17 explains the relapse formation, the drivers behind
disease remission remain elusive. Treg cells are a likely candi-
date for local control of inflammation and are found more
frequently in the skin than in the circulation or other non-
lymphoid tissues (Ali and Rosenblum, 2017). The majority of
peripheral circulating human Treg cells express the skin hom-
ing receptor cutaneous lymphocyte antigen (CLA) and the
chemokine receptor CCR6 (Hirahara et al., 2006). Their impor-
tance in preventing skin disease is most evident in patients
suffering from the immunodysregulation polyendocrinopathy
enteropathy x-linked (IPEX) syndrome caused by mutations
in the Foxp3 gene, where cutaneous inflammation is highly
common and occurs within the first months of life (Goudy
et al., 2013; Halabi-Tawil et al., 2009). Dysfunctional or
reduced Treg cells were also described in blood circulation
and in psoriatic lesional skin in patients (Sugiyama et al.,
2005; Keijsers et al., 2013), and Treg cells were found to be
absent from newly formed acute psoriatic lesions shortly after
disease initiation (Yun et al., 2010).
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Although these data support the notion that Treg cells can
restrain psoriatic skin pathology, the precise mechanism how
Treg cells control psoriasiform skin inflammation is unknown.
In order to address the functional role of Treg cells in skin inflam-
mation, we specifically depleted Foxp3+ Treg cells in the murine
Aldara-induced model of psoriasis (van der Fits et al., 2009).
Aldara-treatedmice develop psoriasiform skin lesionsmimicking
most of the features of the human disease, and therapeutic
agents, which are effective in the model, are equally effective
in the human disease (Pantelyushin et al., 2012; Nestle et al.,
2009). For the specific depletion of Foxp3+ Treg cells, we utilized
Foxp3DTR/+ mice, in which the human diphtheria toxin receptor
(DTR) is inserted into the 30 UTR of the Foxp3 locus. This allowed
us to eliminate Foxp3+ Treg cells at any time point by the injec-
tion of diphtheria toxin (DTx) (Kim et al., 2007). Using this
approach, we found that Treg cells limit the exacerbation of local
skin inflammation and initiate disease remission. Loss of Treg
cells coincided with the emergence of pathogenic GM-CSF-pro-
ducing CD4+ T cells in themurinemodel of psoriasis and with the
occurrence of GM-CSF in ipilimumab-induced skin rashes. Our
study therefore indicates that Treg cells play a pivotal role in
controlling psoriasiform skin inflammation and mediating skin
homeostasis by restraining pathogenic effector cells.
RESULTS
Skin-Invading Foxp3+ Treg Cells Control Aldara-Induced
Skin Inflammation
The pathogenesis of Aldara-induced skin inflammation involves
the emergence of various innate and adaptive immune cells. To
analyze the skin lymphocyte compartment in psoriasiform lesions,
we applied Aldara (5% imiquimod) topically to C57BL/6 mice
(hereafter called wild-type [WT]) for eight days and harvested the
treated skinat daynine. Thiswas followedbysingle-cell cytometry
combined with automated, algorithm-based t-distributed sto-
chastic neighbor embedding (t-SNE) visualization and FlowSOM
clustering of CD3+ cells pre-gated on single, live, CD45+ lympho-
cytes (FigureS1A). Clustering themost prominent lineagemarkers
revealed six distinguishable cell populations in the skin (Figures 1A
and S1B). Namely, skin-resident TCRgdhigh cells (Vg5+ dendritic
epidermal T cells [DETCs]), dermal Vg4+ (TCRgdint) and non-
Vg4+ = Vg6+ cells (TCRgdint), Foxp3+ T cells, CD4+ T cells, and
CD8+ T cells. Aldara treatment induced a slight increase across
all leukocytes in the skin. As expected (Cai et al., 2011; Pante-
lyushin et al., 2012), we observed a dramatic expansion of dermal
Vg4+ cells and the accumulation of Treg cells in psoriatic skin (Fig-
ures 1A and 1B). More precisely, we found a five-fold increase of
Foxp3+ Treg cells in the Aldara-treated skin compared to un-
treated skin, accounting for up to80percent of the total population
of skin-invading CD4+ T cells (Figure 1B). To determine the role of
Treg cells in the immunopathology of psoriasis, we treated
Foxp3DTR/+ mice with Aldara for eight consecutive days and in-
jected 500 ng DTx on day four and six after Aldara treatment initi-
ation (Figure 1C). After injection of DTx in either naive or Aldara-
treatedmice, Tregcells in the skinwere almost completely absent,
demonstrating that local Treg cell depletion was highly efficient
(Figures 1D and 1E). Although skin inflammation in WT mice
peaked at day five and regressed afterward, the disease of Treg-
cell-depletedmicewas dramatically exacerbated (3- to 4-fold), re-
sulting in a steadily increasing thickening of the skin (Figure 1F). To
further address whether Treg cells control the re-emergence of
clinical symptoms after disease remission (hereafter referred as
relapse), WT and Foxp3DTR/+ mice were treated with Aldara for
21 days. In both groups, skin inflammation peaked at day 8 and
declined afterward, despite continuous Aldara treatment. Treg
cell depletion in recovering mice led to a relapse of psoriasiform
skin lesions (Figure S1C). Therefore, we conclude that Treg cells
play a critical role in controlling psoriasiform inflammation.
Emergence of abTCells andPhagocytes in Psoriasiform
Skin Lesions upon Treg Cell Loss
Lesional skin of psoriasis patients is invaded by several immune
cells, including T cells and polymorphonuclear andmononuclear
phagocytes (Nestle et al., 2009). To better understand how Treg
cells control skin inflammation, we analyzed the cellular compo-
sition of the skin at the peak of psoriasiform inflammation in the
presence or absence of Treg cells by flow cytometry. We again
used t-SNE visualization and FlowSOM clustering to analyze
the overall T cell infiltrates depending on their similarity in the
expression of lineage-specificmarkers. The five discernible clus-
ters were TCRgdhigh (DETCs), Vg4, Vg6, ab T cells, and Treg cells
(Figure 2A). To define cell populations based on parameter
expression heatmaps, we followed similar analysis workflow as
shown in Figure S1B. As previously reported, Vg4+ T cells are
the source of IL-17 and IL-22, and as such, the main drivers of
Aldara-induced skin inflammation and ab T cells are (1) not
critical for disease development and (2) almost absent from the
lesional skin (Pantelyushin et al., 2012; Hartwig et al., 2015).
We thus suspected that Treg cells might control the pathogenic
signature cytokines and/or Vg4+T17 cell infiltration into the skin.
However, Vg4+ T cells were not elevated in Treg cell-deficient
mice showing that Treg cells did not directly control the IL-17-
producing pathogenic Vg4+ T cells (Figure 2B). In contrast, we
observed the local accumulation of CD4+ and CD8+ T cells in
Treg-cell-depleted mice, compared to control groups (Figures
2A and 2B). Of note, Treg cell depletion per se did not alter the
composition of the skin leukocyte compartment when the mice
were not challenged with Aldara (Figures 2A and 2B).
We next focused on the myeloid compartment and identified
five distinct clusters, including neutrophils, Ly6C+ monocytes,
monocyte-derived cells (MdCs) and macrophages, Langerhans
cells (LCs), and plasmacytoid dendritic cells (pDCs) (Figure 2C).
Quantification of myeloid subsets showed that neutrophils and
MdCs were the dominant cell types infiltrating the skin in Aldara-
treated Treg cell–deficient mice (Figures 2C and 2D). We also
analyzed the composition of leukocytes within the skin draining
lymph nodes (dLN) and found a relative increase in all populations
led by CD19+ B cells and CD4+ and CD8+ T cells upon Treg cells
depletion (Figure S2A). More detailed phenotyping of T cells in
the dLN showed that the vast majority of CD4 T cells are
CD44+CD62L effector memory T cells in Treg cell-deficient
mice, whereas CD8 T cells were CD44+CD62L+ (Figure S2B).
CD8 T cells also upregulated the early activation antigen CD69
(Figure S2C). Both CD4 and CD8 T cell compartments were pos-
itive for Ki-67, indicative of proliferation (Figure S2D). Together,
our data suggest that Treg cells do not control the initiation of
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psoriasiform lesions or the emergence of gdT17 cells but instead
limit the ability of ab T cells to invade and expand in the lesional
skin and dLNs.
Treg Cells Prevent Expansion of Pathogenic
GM-CSF-Producing CD4+ T Cells in the Skin
Given the importance of IL-17A, IL-17F, IL-22, and tumor necro-
sis factor (TNF) in the formation of psoriasiform lesions, we were
surprised to find no dramatic changes in these cytokines in
Aldara-treated mice upon Treg cell loss (Figure 3A). Instead,
we found the strongest change of cytokine expression among
CD3+ T cells to be GM-CSF (80-fold; Figure 3A). GM-CSF was
mainly produced by CD45+ cells and among them chiefly by
CD4+ T cells (Figures 3B–3D). These GM-CSF+ CD4+ T cells
did not co-produce the psoriasis-associated cytokines IL-22,
IL-17A, and IL-17F (Figure S3A) but were positive for IL-23R
(Figure S3B). We further analyzed common cytokines driving
GM-CSF production in T cells and found elevated levels of
Figure 1. Skin-Invading Foxp3+ Treg Cells Control Aldara-Induced Skin Inflammation
(A and B) Ears of WT mice were treated topically with Aldara for eight consecutive days, and skin lymphocytes were analyzed by flow cytometry on day nine.
(A) CD45+CD3+ cells were used for algorithm-based t-SNE visualization and FlowSOM clustering based on their expression of T-cell-specific lineage markers
(see also Figure S1B).
(B) Bar charts show total numbers (left) and percentages (right) of Foxp3+CD3+ cells from naive and Aldara-treated mice.
(C–F) Foxp3DTR/+ andWTmicewere treated daily with Aldara (red) on the ears for eight days or were left untreated (black), and skin lymphocytes were analyzed by
flow cytometry on day nine. All groups were injected intraperitoneally (i.p.) with 500 ng DTx on day four and day six after Aldara treatment initiation.
(C) Schematic illustration of the experimental setup.
(D) Representative contour plots show the percentage of CD4+Foxp3+ T cells (pre-gated on CD45+CD3+ cells).
(E) Bar graphs show the total cell numbers (left) and frequencies (right) of CD4+Foxp3+ T cells.
(F) Kinetics of skin inflammation depicted as percentage increase in ear thickness. Two-way ANOVA with Bonferroni’s posttest is shown.
In (A), (B), and (D)–(F), displayed results are representative of three independent experiments (n = 3–5). In (B) and (E), data are shown as mean ± SEM two-tailed
Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. DTx, diphtheria toxin; WT, wild-type.
See also Figure S1.
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Figure 2. Accumulation of ab T Cells and Phagocytes in Psoriasiform Skin Lesions upon Treg Cell Loss
(A–D) Foxp3DTR/+ and WT mice were challenged with Aldara on their ears for eight consecutive days (red) or were left untreated (black). 500 ng DTx was injected
i.p. on day four and six after Aldara treatment initiation. Skin lymphocytes were analyzed on day nine by flow cytometry.
(A) CD45+CD3+ cells were visualized by t-SNE and clustered by FlowSOM depending on their similarity in the expression of lineage-specific markers.
(B) Total cell numbers (±SEM) of CD4+Foxp3, CD8+, TCRgdhigh, TCRgdint, and Vg4+ cells.
(C) CD45+CD19 cells were used for t-SNE visualization and FlowSOM clustering.
(D) Total cell numbers (±SEM) of neutrophils, MdCs, Ly6C+ monocytes, LCs, and pDCs.
(legend continued on next page)
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pro-IL-1b but failed to observe major changes in the expression
of Il23a or Il12a (Figure S3C). We identified skin-invading Ly6-
Chigh monocytes and neutrophils as the chief producers of pro-
IL-1b in Aldara-treated Treg cell-deficient mice (Figure S3D).
To determine whether the Treg cell–dependent control of GM-
CSF-producing T cells is the reason for the observed hyper-
inflammation in Aldara-treated Treg cell-deficient mice, we
employed either a neutralizing anti-GM-CSF antibody or GM-
CSF-deficient mice. Foxp3DTR/+ mice were injected with 300 mg
of anti-GM-CSFantibody (Ab) every secondday until day six after
Aldara treatment start (Figure 4A). Neutralization or loss of GM-
CSF in Treg-cell-depleted mice reversed skin inflammation to
WT levels (Figure 4B). Importantly, GM-CSF neutralization did
not stop the accumulation of GM-CSF-producing T helper (TH)
cells in the skin of Treg-cell-depleted mice (Figure 4C). This is
not surprisingbecauseTcells generally donot express the recep-
tor complex for sensing GM-CSF. Also, this indicates that GM-
CSF+ TH cells in the skin are directly controlled by Treg cells
and that the elevated frequency of GM-CSF+ TH cells is not the
result of enhanced skin inflammation per se. Histological analysis
revealed that the increased epidermal thickness found in Treg-
cell-depleted mice was reduced in the absence of csf2 (Figures
4D and 4E). Our data demonstrate that Treg cells control the
occurrence of hyper-active pathogenic effector T cells, which
produce GM-CSF and subsequent immunopathology.
To support our findings of GM-CSF appearance following Treg
cell depletion in mice, also in human skin, we analyzed GM-CSF
levels of ipilimumab (a-CTLA-4 monoclonal antibody [mAb])-
induced skin rashes. Treatment of melanoma patients with
ipilimumab (IP) can cause severe skin manifestations and
pathologies by neutralization of Treg cells (Bertrand et al., 2015;
Romano et al., 2015). Comparing ipilimumab-induced flares
with skin from healthy donors (HC), we observed higher levels
of Csf2 mRNA transcripts in the skin from ipilimumab (Figures
S4A and S4B), suggesting that Treg cells may have a universal
role in maintaining skin homeostasis and that conversely pertur-
bations of Treg cells could initiate skin pathologies.
DISCUSSION
Psoriasis has been considered as a Th1-driven skin dis-
ease for almost 30 years. After the discovery of pathogenic
Two-tailed Student’s t test was used in (B) and (D). *p < 0.05; **p < 0.01; ***p < 0.001.
In (A)–(D), a representative experiment (n = 2–4) of three independent experiments is shown. LCs, Langerhans cells; MdCs, monocyte-derived cells; pDCs,
plasmacytoid dendritic cells.
See also Figure S2.
Figure 3. Treg Cells Prevent Expansion of Pathogenic GM-CSF-Producing CD4+ T Cells in the Skin
(A–D) Foxp3DTR/+ and WTmice were treated with Aldara daily on the ear for eight days. On day four and six, both groups were injected i.p. with 500 ng DTx. Flow
cytometric analysis of skin lymphocytes was performed on day nine.
(A) Heatmap showing fold change in cytokine expression of CD3+ cells normalized to Aldara-treated WT mice.
(B) Total skin cells (left) or GM-CSF-producing cells (right) were visualized using t-SNE algorithm and clustered by FlowSOM depending on their similarity in the
expression of linage-specific markers (left).
(C) Donut charts showing percentages of GM-CSF-expressing cells from Aldara- and DTx-treated Foxp3DTR/+ mice. CD45+ and CD45 cells (left) and DETCs,
CD8+, CD11b+, Ly6C+, TCRgd+, and CD4+ cells (right) are shown.
(D) Percentages of GM-CSF-producing CD4+ T cells from the LN (left) and total cell numbers from the skin (right; ± SEM).
In (A)–(D), one representative of three independent experiments (n = 3–5) is shown.
Two-tailed Student’s t test is shown. *p < 0.05; **p < 0.01; ***p < 0.001. DETCs, dendritic epidermal T cells.
See also Figure S3.
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IL-17-producing T cells in psoriasis, this paradigm shifted
completely and new therapeutic approaches against the IL-23-
IL-17 pathway were successfully introduced (Nast et al., 2012;
Langley et al., 2014). To date, these therapies are mostly directed
against the pathogenic drivers of the disease, disregarding poten-
tial pathways regulating the disease chronification. Although Treg
cells maintain immune tolerance through various well-character-
ized mechanisms (Walker, 2013; Sakaguchi et al., 2008), the
mechanisms and dynamics by which Treg cells control ongoing
psoriasiform skin inflammation are still not completely under-
stood. To address how Treg cells contribute to skin inflammation,
weutilizedFoxp3DTRmice toeliminateTregcells inamurinemodel
of psoriasis. We found that Treg cells accumulate and control the
exacerbation of skin inflammation by restraining pathogenic GM-
CSF-producing CD4+ T cells. Even though the IL-23-IL-17 axis is
clearly driving the pathogenesis of psoriasis, the role of dysregu-
lated GM-CSF expression in the skin is still a matter of debate.
Pointing toward the contribution of GM-CSF in disease develop-
ment, recombinant GM-CSF therapy for the treatment of neutro-
penia following chemotherapy led to relapsing and exacerbating
psoriasis flares in breast cancer patients (Cho et al., 1998).
Accordingly, a recent study found neutralization of GM-CSF to
reduce skin pathology in Aldara-driven psoriasis (Scholz et al.,
2017). Nonetheless, a recent phase II clinical trial showed no
benefit of the use of anti-GM-CSFAbs (namilumab) in plaque pso-
riasis (https://clinicaltrials.gov/: NCT02129777; Papp et al., 2018).
Of note, the penetration of Abs into skin is much lower than into
joints of rheumatoidarthritis patients, inwhich namilumabdemon-
strated a high efficacy (Choy et al., 2000;Pappet al., 2018; https://
clinicaltrials.gov/: NCT023790091).
Importantly, we found exacerbated skin inflammation and
elevated GM-CSF levels only in the absence of Treg cells, but
not in psoriasiform inflammation of Treg cell–sufficient WT
mice. Neutralization of GM-CSF in Treg cell-deficient mice
Figure 4. Neutralizing GM-CSF in Treg Cell-Deficient Mice Reverses Hyper-inflammation
(A–E) WT, Foxp3DTR/+, and Foxp3DTR/+Csf2/mice were treated topically with Aldara on their ears for eight consecutive days, and DTx was injected i.p. on days
four and six. Additionally, one Foxp3DTR/+ group was injected i.p. with anti-GM-CSF antibody every second day starting at day 0.
(A) Schematic illustration of the experimental setup.
(B) Kinetics of skin inflammation depicted as percentage increase in ear thickness (±SEM); two-way ANOVA with Bonferroni’s posttest.
(C) Percentage (±SEM) of GM-CSF-expressing CD4+ T cells (pre-gated on CD45+CD11b lymphocytes) analyzed by flow cytometry on day nine.
(D and E) On day nine, ears were Hepes-glutamic acid buffer-mediated organic solvent protection effect (HOPE) fixed and sections were stained with H&E.
(D) Representative images. Scale bars 220 mm.
(E) Bar graph showing epidermal thickening measured on images of H&E stainings.
In (A)–(C), one representative of three independent experiments (n = 3–5) is shown. In (D) and (E), one representative of two independent experiments (n = 3–4) is
shown.
Two-tailed Student’s t test is shown. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant.
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reversed hyper-inflammation to WT levels, suggesting that GM-
CSF is not important for disease initiation but is driving the
aggravation of established skin lesions. Given that GM-CSF is
part of a cytokine network, it is likely that targeting of GM-CSF
further changes several downstream cytokines involved in Treg
cell–regulated inflammation.
The fact that GM-CSF is upregulated in human skin rashes
induced by a-CTLA4 supports a general function of Treg cells
controlling skin inflammation and suggests that Treg cells are
vital in maintaining skin homeostasis. GM-CSF has emerged
as an essential communication conduit between inflammatory
T cells and tissue-invading phagocytes (Becher et al., 2016,
2017). Here, psoriasiform skin lesions were preferentially
invaded by neutrophils and monocytes, both well-described
cell types responding to GM-CSF (Ko et al., 2014; Kroenke
et al., 2010; Croxford et al., 2015).
So far, we can only speculate by which molecular mechanism
Treg cells control pathogenic skin CD4+ T cells. It is very likely
that the loss of Treg cells licenses skin-resident DCs to initiate
their pathogenic program, including exacerbated secretion of
cytokines. In support of this idea, we observed the enhanced de-
livery of IL-1b into the lesioned skin of mice in which Treg cells
have been depleted. IL-1b in turn is well established to induce
GM-CSF expression in T cells (El-Behi et al., 2011). In other
studies, Treg cells have been shown to limit DC functions and
thus T cell responses by CTLA-4 and Lag3 in a contact-depen-
dent manner (Vignali et al., 2008). However, effector T cells can
also be directly controlled by inhibitory Treg cell–derived cyto-
kines, such as IL-10 and transforming growth factor b (TGF-b).
Another possibility of accumulated effector T cell in the skin
upon Treg cell depletion is the excess of IL-2 at the inflammation
site. IL-2 directly induces GM-CSF expression (Hartmann et al.,
2014), and Treg cells capture IL-2, thereby reducing the prolifer-
ation of other T cells.
In summary, we identified a pathway by which Treg cells sup-
press the exacerbation of psoriasiform inflammation through the
control of pathogenic GM-CSF-producing ab T cells, suggesting
that this interplay contributes to the relapsing-remitting nature of
the disease.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-mouse CD45 clone 30-F11, Pacific Blue BioLegend Cat # 103125; RRID: AB_493536
anti-mouse CD3 clone 17A2, Alexa Fluor 700 Thermo Fisher Scientific Cat# 56-0032-80; RRID: AB_529508
anti-mouse CD8a clone 53-6.7, PE-CF594 BD Cat 562283; RRID: AB_11152075
anti-mouse CD4 clone RM4-5, Brilliant Violet 605 BioLegend Cat# 100548; RRID: AB_2563054
anti-mouse Foxp3 clone FJK-16 s, PE Thermo Fisher Scientific Cat# 12-5773-80; AB_465935
anti-mouse CD11b clone M1/70, APC- Cy7 BD Cat# 557657; AB_396772
anti-mouse Ki67 clone SolA15, PE- Cy7 Thermo Fisher Scientific Cat# 25-5698-80; RRID: AB_11217689
anti-mouse TCRgd clone GL3, FITC BioLegend Cat# 118105; RRID: AB_313829
anti-mouse I-A/I-E clone M5/114.15.2, BB700 BD Cat# 746197; RRID: AB_2743544
anti-mouse Ly-6G clone 1A8, BV650 BioLegend Cat# 127641; RRID: AB_2565881
anti-mouse Ly-6G clone 1A8, Alexa Fluor 700 BioLegend Cat# 127622; RRID: AB_10643269
anti-mouse Ly-6C clone AL-21, FITC BD Cat# 553104; RRID: AB_394628
anti-mouse Vg5 clone 536, PE BioLegend Cat# 137504; RRID: AB_10550807
anti-mouse Vg4 clone UC3-10A6, PerCP-eFluor 710 Thermo Fisher Scientific Cat# 46-5828-80; RRID: AB_2573772
anti-mouse IL-17A clone TC11-18H10.1, PE-Cy7 BioLegend Cat# 506922; RRID: AB_2125010
anti-mouse IL-22 clone IL22JOP, APC Thermo Fisher Scientific Cat# 17-7222-80; RRID: AB_10597584
anti-mouse CD11c clone N418, PE-Cy5.5 Thermo Fisher Scientific Cat# 35-0114-82; RRID: AB_469709
anti-mouse IL-17F clone O79-289, PE-CF594 BD Cat# 562418; RRID: AB_11154042
anti-mouse CD207 (Langerin) clone 4C7, APC BioLegend Cat# 144206; RRID: AB_2561998
anti-mouse CD14 clone Sa14-2, Brilliant Violet 510 BioLegend Cat# 123323; RRID: AB_2564129
anti-mouse CD64 clone X54-5/7.1, Brilliant Violet 710 BioLegend Cat# 139311; RRID: AB_2563846
anti-mouse CD24 clone M1/69, BUV496 BD Cat# 564664; RRID: AB_2716853
anti-mouse CD103 clone 2E7, PE BioLegend Cat# 121406; RRID: AB_1133989
anti-mouse F4/80 clone BM8, PE-Cy5 BioLegend Cat# 123111; RRID: AB_893494
anti-mouse B220 clone RA3-6B2, Brilliant Violet 785 BioLegend Cat# 103245; RRID: AB_11218795
anti-mouse CD169 clone 3D6.112, Brilliant Violet 605 BioLegend Cat# 142413; RRID: AB_2564030
anti-mouse CD69 clone H1.2F3, PE-Cy7 BD Cat# 552879; RRID: AB_394508
anti-mouse CD62L clone MEL-14, FITC BD Cat# 553150; RRID: AB_394665
anti-mouse CD44 clone IM7, PE BD Cat# 55313; RRID: AB_394649
anti-mouse CD19 clone 6D5, Pacific Blue BioLegend Cat# 115523; RRID: AB_439718
anti-mouse TNF-a clone MP6-XT22, Brilliant Violet 711 BioLegend Cat# 506349; RRID: AB_2629800
anti-mouse GM-CSF clone MP1-22E9, PE Thermo Fisher Scientific Cat# 12-7331-82; RRID: AB_466205
rat anti-human GM-CSF clone BVD2-21C11, APC BD Cat# 502309; RRID: AB_11148950
mouse anti-human Foxp3 clone 236A/E7 Thermo Fisher Scientific Cat# 14-4777-80; RRID: AB_467555
rabbit anti-human CD3 clone SP7 Novus Biologicals Cat# NB600-1441SS
Goat anti-rat Alexa Fluor 647 Thermo Fisher Scientific Cat# A-21247; RRID: AB_141778
Goat anti-mouse Alexa Fluor 488 Thermo Fisher Scientific Cat# A-11029; RRID: AB_138404
Goat anti-rabbit Alexa Fluor 555 Thermo Fisher Scientific Cat# A-21428; RRID: AB_141784
LEAF Purified anti-mouse GM-CSF BioLegend Cat# 505407; AB_315383
anti-mouse GM-CSF clone MP1-31G6, Biotin Thermo Fisher Scientific Cat# 13-7332-85; RRID: AB_466949
anti-mouse CD45 clone 30-F11, Biotin BioLegend Cat# 103104; RRID: AB_312969
Chemicals, Peptides, and Recombinant Proteins
Diphteria Toxin Calbiochem Cat# 322326
Aldara (5% Imiquimod) 3M Pharmaceuticals N/A
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by Lead Contact Burkhard Becher (becher@
immunology.uzh.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
C57BL/6 mice (WT) were purchased from Janvier Laboratory. Foxp3DTR/+ mice were generated by Kim et al. (2007) and kindly pro-
vided by Markus Feuerer (DKFZ Heidelberg, Germany). Csf2/ mice were provided by Glenn Dranoff (Dranoff et al., 1994), back-
crossed to C57BL/6 using speed congenics and crossed to Foxp3DTR/+ mice. Male and female mice were used in all experiments
(6-12 weeks old) and housed in specific pathogen free conditions. All experiments were approved by the Cantonal Veterinary Office
Zurich.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
PBS Homemade N/A
Ionomycin calcium salt from Streptomyces conglobatus Sigma-Aldrich CAS: 56092-82-1
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich CAS: 16561-29-8
Deoxyribonuclease (DNase) I from bovine pancreas Sigma-Aldrich CAS: 9003-98-9
Golgi Stop BD Cat# 554724
Golgi Plug BD Cat# 555029
Collagenase from Clostridium histolyticum (Collagenase IV) Sigma-Aldrich CAS: 9001-12-1
Avidin Thermo Fisher Scientific Cat# A2667
M-MLV reverse transcriptase Invitrogen Cat# 28025013
iTaq Universal SYBR Green Supermix Bio-Rad Cat# 1725124
SlowFade Gold antifade reagent with DAPI Thermo Fisher Scientific Cat# S36938
Cytofix/Cytoperm BD Cat#554714
eBioscience Foxp3/Transcription Factor Fixation/
Permeabilization Concentrate and Diluent
Thermo Fisher Scientific Cat# 00-5521-00
Permeabilization Buffer Homemade N/A
Critical Commercial Assays
RNeasy FFPE Kit QIAGEN Cat# 73509
Quick-RNA MiniPrep Kit ZYMO RESEARCH SKU 1054
Experimental Models: Organisms/Strains
C57BL/6JRJ The Janvier Labs RRID:MGI:5752053
Foxp3DTR/+: B6N.129(Cg)-Foxp3tm3Ayr provided by Markus Feurerer;
Kim et al., 2007
N/A
Csf2/: Csf2tm1Jaw provided by Glenn Dranoff;
Dranoff et al., 1994
N/A
Oligonucleotides
Primers for qPCR see Table S1 This paper N/A
Software and Algorithms
FlowJo v10.2 Tree Star https://www.flowjo.com/
MATLAB R2016a N/A https://www.mathworks.com/
CYT Amir et al., 2013 N/A
t-SNE van der Maaten and Hinton, 2008 https://github.com/jkrijthe/Rtsne
FlowSOM Van Gassen et al., 2015 https://github.com/SofieVG/FlowSOM
R studio N/A https://www.rstudio.com/
IMARIS N/A http://www.bitplane.com
GraphPad Prism 7 N/A https://www.graphpad.com
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Human studies
Analysis of retrospective patient samples from St.Gallen was approved by the local Research Ethics Committee (Ethikkommission
Ostschweiz): BASEC- Project ID: 2016-01161 47 and EK800 entitled for the project entitled: ‘‘Retrospective histopathological char-
acterization of lymph node metastases and correlation with response to immunotherapy in melanoma patients.’’ Surplus tumor ma-
terial was obtained after surgical removal of melanoma metastases from patients after written informed consent approved by the
local IRB (EK647 and EK800).
METHOD DETAILS
In vivo treatments
Micewere anesthetizedwith isoflurane andAldara treatment was performed by applying daily 8mgAldara cream (5% Imiquimod; 3M
Pharmaceuticals) on each mouse ear for the duration indicated in the text. DTx (Calbiochem, 500ng per mouse in PBS) was injected
intraperitoneally (i.p.) on day 4 and 6 or 10 and 12 after starting the Aldara treatment. Anti-GM-CSF treatment was performed every
second day by i.p. injection of 300 mg rat anti-mouse GM-CSF monoclonal Ab.
Tissue processing
Ears were cut into small pieces and digested in 5ml RPMI containing 1mg/ml Collagenase type IV and 100 mg/ml DNase I (both
Sigma-Aldrich) while shaking at 37C for 90 minutes. The tissue was further homogenized with a syringe and filtered through a
70 mm cell strainer. The cell strainer was washed with 20ml PBS followed by centrifugation (500 x g at 4C for 10min).
Single cell suspensions from the LNswere obtained bymashing the LNs through 70 mmcell strainers. Single cells were then stained
with fluorescence antibodies for Flow Cytometry.
Flow Cytometry
All utilized antibodies are summarized in the Key Resources Table. For surface staining, leukocytes isolated from the skin or the LNs
were incubated with antibodies at 4C for 20min. For intracellular cytokine staining, cells were re-stimulated in 1ml RPMI supple-
mented with Golgi-Stop or Golgi-Plug (1:1000, BD), PMA (50ng/ml, Applichem) and Ionomycin (500ng/ml, Invitrogen) for 4 hours
at 37C. After surface staining, cells were permeabilized and fixed in 200ml BD Cytofix/CytopermTM according to the manufacturer’s
instructions. Then, cells were washed with Permeabilization buffer and stained intracellularly at 4C for 20min in Permeabilization
buffer. For intranuclear staining, cells were fixed and permeabilized using the eBioscience Foxp3/transcription factor fixation/perme-
abilization concentrate and diluent from ThermoFisher followed by incubation with antibodies at 4C for 20min. Acquisition was per-
formed with FACS LSRII Fortessa or FACSymphony (both BD). Flow cytometric analysis on live, single cells was performed using
FlowJo (Tree Star) software.
For surface capture of GM-CSF expressing cells (Streeck et al., 2008), after re-stimulation with PMA and Ionomycin, cells
were incubated with GM-CSF capture complexes consisting of biotin-labeled anti-GM-CSF and anti-CD45 antibodies linked by
an avidin bridge. (Invitrogen). After cell surface staining CD4+ and CD4+ GM-CSF secreting T cells were sorted using FACS AriaIII
5L (BD).
Patient ID Age Sex Treatment
HS18.18 36 f no
HS18.27 29 f no
K79c 31 f no
K81b 57 f no
K82d 27 m no
K83a 45 f no
H2015.8272 77 m Ipilimumab
H2012.11567 64 m Ipilimumab
B2011.58537 84 m Ipilimumab
B2013.7833 84 m Ipilimumab
HG2012.470 71 m Ipilimumab
HG14.570 78 m Ipilimumab
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Quantitative RT-PCR (qRT-PCR)
RNA was isolated from formalin-fixed, paraffin embedded tissue sections from healthy control skin or skin rashes of Ipilimumab-
treated melanoma patients using the RNeasy FFPE Kit (QIAGEN) according to the manufactures instructions. RNA from snap-frozen
human and murine skin or from sorted cells was isolated using the Quick-RNA MiniPrep Kit (Zymo Research). RNA was reverse
transcribed to cDNA with M-MLV reverse transcriptase (Invitrogen). qRT-PCR was performed on a C1000 Touch Thermo Cycler
(Bio-Rad) using SYBR Green (Bio-Rad) and primers described in Table S1. For DNA amplification a 3min incubation at 95C was
followed by 40 cycles with 10 s at 95C and 45 s at 60C.
Histology
For histo-pathological analysis, ear skin was fixed in HOPE, embedded in paraffin and 10 mm sections were cut using a microtome
(Micro HM 325, Thermo Scientific). Subsequently, the sections were stained with hematoxylin and eosin (H&E) and were analyzed
with a light microscope (Olympus BX41). Epidermal thickness was measured and cell infiltrates were counted on one representative
image per sample. Mean of 3 measurements was calculated.
Immunofluorescence of human samples was performed on skin tissue from 3 biopsied healthy donors and 2with Ipilimumab-asso-
ciated dermatitis. Tissues were cryosectioned (12 mm thick) for immunofluorescence using a Hyrax C60 cryostat (Zeiss) and stored at
80C. Skin sections were fixed in 2% PFA and acetone, washed in PBS, and blocked with PBS supplemented with 0.1% Triton
X-100 and 4% normal goat serum. Subsequently, sections were incubated with the following primary antibodies (diluted in blocking
solution) overnight at 4C: rat anti-GM-CSF antibody (BD PharMingen, clone BVD2-21C11, 1:50), mouse anti-FoxP3 antibody
(Invitrogen, clone 236A/E7, 1:20) and rabbit anti-CD3 (Novus, clone SP7, 1:100). Sections were then washed in PBS and incubated
with AF647-labeled goat anti-rat, AF488-labeled goat anti-mouse and AF555-labeled goat anti-rabbit secondary antibodies (Life
Technologies, 1:250-500) overnight at 4C or at room temperature for 1 h. Sections were mounted with SlowFade Gold antifade re-
agent with DAPI (Invitrogen). Fluorescence photomicrographs were captured with a SP5 Leica confocal laser scanning microscope
(SP5; Leica, Heerbrug, Switzerland) equipped with argon and helium lasers using the 40x or 60x objective (oil immersion, NA1.25 and
NA 1.4 respectively). Images were processed and merged by Imaris imaging software (Bitplane, Zurich, Switzerland).
t-SNE visualization
FCS files of live, single cells were exported from FlowJo and transformed in CYT (MATLAB) (Amir et al., 2013) using the hyperbolic
arcsine (arcsinh) function and percentile normalization in R. Pre-processed data was subsequently used as input for t-SNE visuali-
zation (van der Maaten and Hinton, 2008) and FlowSOM clustering (Van Gassen et al., 2015) following the workflow and script from
Hartmann et al. (2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
For disease curves, statistics were evaluated using 2-way ANOVA with Bonferroni‘s post-test. Differences between three or more
experimental groups were analyzed using 1-way ANOVA. For comparison of two sets of data 2-tailed Student‘s t test was used. Sta-
tistical analysis was performed using GraphPad Prism (GraphPad Software). Statistical details of the data can be found in each figure
legend. p% 0.05 was defined as significant.
e4 Cell Reports 25, 3564–3572.e1–e4, December 26, 2018
